カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のアンチセンス＆RNA干渉治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Antisense and RNA Interference Therapeutics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19152）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19152
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：92
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のアンチセンス＆RNA干渉治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

アンチセンス＆RNA干渉治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のアンチセンス＆RNA干渉治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

アンチセンス＆RNA干渉治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・RNA、アンチセンスRNA

用途別セグメントは次のように区分されます。
・総合病院、専門クリニック

世界のアンチセンス＆RNA干渉治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Alnylam Pharmaceuticals、Antisense Therapeutics、Arbutus Biopharma、Ionis Pharmaceuticals、F. Hoffmann-La Roche、Santaris、Silence Therapeutics、Sirnaomics、Tekmira Pharmaceuticals

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、アンチセンス＆RNA干渉治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なアンチセンス＆RNA干渉治療薬メーカーの企業概要、2019年～2022年までのアンチセンス＆RNA干渉治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なアンチセンス＆RNA干渉治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別アンチセンス＆RNA干渉治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのアンチセンス＆RNA干渉治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのアンチセンス＆RNA干渉治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびアンチセンス＆RNA干渉治療薬の産業チェーンを掲載しています。
・第13、14、15章では、アンチセンス＆RNA干渉治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- アンチセンス＆RNA干渉治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：RNA、アンチセンスRNA
- 用途別分析（2017年vs2021年vs2028年）：総合病院、専門クリニック
- 世界のアンチセンス＆RNA干渉治療薬市場規模・予測
- 世界のアンチセンス＆RNA干渉治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Alnylam Pharmaceuticals、Antisense Therapeutics、Arbutus Biopharma、Ionis Pharmaceuticals、F. Hoffmann-La Roche、Santaris、Silence Therapeutics、Sirnaomics、Tekmira Pharmaceuticals
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：RNA、アンチセンスRNA
・用途別分析2017年-2028年：総合病院、専門クリニック
・アンチセンス＆RNA干渉治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・アンチセンス＆RNA干渉治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・アンチセンス＆RNA干渉治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・アンチセンス＆RNA干渉治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・アンチセンス＆RNA干渉治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Antisense and RNA Interference Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Antisense and RNA Interference Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. General Hospitals accounting for % of the Antisense and RNA Interference Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While RNA segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Antisense and RNA Interference Therapeutics include Alnylam Pharmaceuticals, Antisense Therapeutics, Arbutus Biopharma, Ionis Pharmaceuticals, and F. Hoffmann-La Roche, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Antisense and RNA Interference Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
RNA
Antisense RNA
Market segment by Application can be divided into
General Hospitals
Specialty Clinics
The key market players for global Antisense and RNA Interference Therapeutics market are listed below:
Alnylam Pharmaceuticals
Antisense Therapeutics
Arbutus Biopharma
Ionis Pharmaceuticals
F. Hoffmann-La Roche
Santaris
Silence Therapeutics
Sirnaomics
Tekmira Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antisense and RNA Interference Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Antisense and RNA Interference Therapeutics, with price, sales, revenue and global market share of Antisense and RNA Interference Therapeutics from 2019 to 2022.
Chapter 3, the Antisense and RNA Interference Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antisense and RNA Interference Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Antisense and RNA Interference Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense and RNA Interference Therapeutics.
Chapter 13, 14, and 15, to describe Antisense and RNA Interference Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Antisense and RNA Interference Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Antisense and RNA Interference Therapeutics Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 RNA
1.2.3 Antisense RNA
1.3 Market Analysis by Application
1.3.1 Overview: Global Antisense and RNA Interference Therapeutics Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 General Hospitals
1.3.3 Specialty Clinics
1.4 Global Antisense and RNA Interference Therapeutics Market Size & Forecast
1.4.1 Global Antisense and RNA Interference Therapeutics Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Antisense and RNA Interference Therapeutics Sales in Volume (2017-2028)
1.4.3 Global Antisense and RNA Interference Therapeutics Price (2017-2028)
1.5 Global Antisense and RNA Interference Therapeutics Production Capacity Analysis
1.5.1 Global Antisense and RNA Interference Therapeutics Total Production Capacity (2017-2028)
1.5.2 Global Antisense and RNA Interference Therapeutics Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Antisense and RNA Interference Therapeutics Market Drivers
1.6.2 Antisense and RNA Interference Therapeutics Market Restraints
1.6.3 Antisense and RNA Interference Therapeutics Trends Analysis
2 Manufacturers Profiles
2.1 Alnylam Pharmaceuticals
2.1.1 Alnylam Pharmaceuticals Details
2.1.2 Alnylam Pharmaceuticals Major Business
2.1.3 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product and Services
2.1.4 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Antisense Therapeutics
2.2.1 Antisense Therapeutics Details
2.2.2 Antisense Therapeutics Major Business
2.2.3 Antisense Therapeutics Antisense and RNA Interference Therapeutics Product and Services
2.2.4 Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Arbutus Biopharma
2.3.1 Arbutus Biopharma Details
2.3.2 Arbutus Biopharma Major Business
2.3.3 Arbutus Biopharma Antisense and RNA Interference Therapeutics Product and Services
2.3.4 Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Ionis Pharmaceuticals
2.4.1 Ionis Pharmaceuticals Details
2.4.2 Ionis Pharmaceuticals Major Business
2.4.3 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product and Services
2.4.4 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 F. Hoffmann-La Roche
2.5.1 F. Hoffmann-La Roche Details
2.5.2 F. Hoffmann-La Roche Major Business
2.5.3 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product and Services
2.5.4 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Santaris
2.6.1 Santaris Details
2.6.2 Santaris Major Business
2.6.3 Santaris Antisense and RNA Interference Therapeutics Product and Services
2.6.4 Santaris Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Silence Therapeutics
2.7.1 Silence Therapeutics Details
2.7.2 Silence Therapeutics Major Business
2.7.3 Silence Therapeutics Antisense and RNA Interference Therapeutics Product and Services
2.7.4 Silence Therapeutics Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Sirnaomics
2.8.1 Sirnaomics Details
2.8.2 Sirnaomics Major Business
2.8.3 Sirnaomics Antisense and RNA Interference Therapeutics Product and Services
2.8.4 Sirnaomics Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Tekmira Pharmaceuticals
2.9.1 Tekmira Pharmaceuticals Details
2.9.2 Tekmira Pharmaceuticals Major Business
2.9.3 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product and Services
2.9.4 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Antisense and RNA Interference Therapeutics Breakdown Data by Manufacturer
3.1 Global Antisense and RNA Interference Therapeutics Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Antisense and RNA Interference Therapeutics Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Antisense and RNA Interference Therapeutics
3.4 Market Concentration Rate
3.4.1 Top 3 Antisense and RNA Interference Therapeutics Manufacturer Market Share in 2021
3.4.2 Top 6 Antisense and RNA Interference Therapeutics Manufacturer Market Share in 2021
3.5 Global Antisense and RNA Interference Therapeutics Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Antisense and RNA Interference Therapeutics Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Antisense and RNA Interference Therapeutics Market Size by Region
4.1.1 Global Antisense and RNA Interference Therapeutics Sales in Volume by Region (2017-2028)
4.1.2 Global Antisense and RNA Interference Therapeutics Revenue by Region (2017-2028)
4.2 North America Antisense and RNA Interference Therapeutics Revenue (2017-2028)
4.3 Europe Antisense and RNA Interference Therapeutics Revenue (2017-2028)
4.4 Asia-Pacific Antisense and RNA Interference Therapeutics Revenue (2017-2028)
4.5 South America Antisense and RNA Interference Therapeutics Revenue (2017-2028)
4.6 Middle East and Africa Antisense and RNA Interference Therapeutics Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Antisense and RNA Interference Therapeutics Sales in Volume by Type (2017-2028)
5.2 Global Antisense and RNA Interference Therapeutics Revenue by Type (2017-2028)
5.3 Global Antisense and RNA Interference Therapeutics Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Antisense and RNA Interference Therapeutics Sales in Volume by Application (2017-2028)
6.2 Global Antisense and RNA Interference Therapeutics Revenue by Application (2017-2028)
6.3 Global Antisense and RNA Interference Therapeutics Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Antisense and RNA Interference Therapeutics Sales by Type (2017-2028)
7.2 North America Antisense and RNA Interference Therapeutics Sales by Application (2017-2028)
7.3 North America Antisense and RNA Interference Therapeutics Market Size by Country
7.3.1 North America Antisense and RNA Interference Therapeutics Sales in Volume by Country (2017-2028)
7.3.2 North America Antisense and RNA Interference Therapeutics Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Antisense and RNA Interference Therapeutics Sales by Type (2017-2028)
8.2 Europe Antisense and RNA Interference Therapeutics Sales by Application (2017-2028)
8.3 Europe Antisense and RNA Interference Therapeutics Market Size by Country
8.3.1 Europe Antisense and RNA Interference Therapeutics Sales in Volume by Country (2017-2028)
8.3.2 Europe Antisense and RNA Interference Therapeutics Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Type (2017-2028)
9.2 Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Application (2017-2028)
9.3 Asia-Pacific Antisense and RNA Interference Therapeutics Market Size by Region
9.3.1 Asia-Pacific Antisense and RNA Interference Therapeutics Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Antisense and RNA Interference Therapeutics Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Antisense and RNA Interference Therapeutics Sales by Type (2017-2028)
10.2 South America Antisense and RNA Interference Therapeutics Sales by Application (2017-2028)
10.3 South America Antisense and RNA Interference Therapeutics Market Size by Country
10.3.1 South America Antisense and RNA Interference Therapeutics Sales in Volume by Country (2017-2028)
10.3.2 South America Antisense and RNA Interference Therapeutics Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type (2017-2028)
11.2 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application (2017-2028)
11.3 Middle East & Africa Antisense and RNA Interference Therapeutics Market Size by Country
11.3.1 Middle East & Africa Antisense and RNA Interference Therapeutics Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Antisense and RNA Interference Therapeutics and Key Manufacturers
12.2 Manufacturing Costs Percentage of Antisense and RNA Interference Therapeutics
12.3 Antisense and RNA Interference Therapeutics Production Process
12.4 Antisense and RNA Interference Therapeutics Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Antisense and RNA Interference Therapeutics Typical Distributors
13.3 Antisense and RNA Interference Therapeutics Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Antisense and RNA Interference Therapeutics Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Antisense and RNA Interference Therapeutics Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Alnylam Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Alnylam Pharmaceuticals Major Business
Table 5. Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product and Services
Table 6. Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Antisense Therapeutics Basic Information, Manufacturing Base and Competitors
Table 8. Antisense Therapeutics Major Business
Table 9. Antisense Therapeutics Antisense and RNA Interference Therapeutics Product and Services
Table 10. Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Arbutus Biopharma Basic Information, Manufacturing Base and Competitors
Table 12. Arbutus Biopharma Major Business
Table 13. Arbutus Biopharma Antisense and RNA Interference Therapeutics Product and Services
Table 14. Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Ionis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Ionis Pharmaceuticals Major Business
Table 17. Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product and Services
Table 18. Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. F. Hoffmann-La Roche Basic Information, Manufacturing Base and Competitors
Table 20. F. Hoffmann-La Roche Major Business
Table 21. F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product and Services
Table 22. F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Santaris Basic Information, Manufacturing Base and Competitors
Table 24. Santaris Major Business
Table 25. Santaris Antisense and RNA Interference Therapeutics Product and Services
Table 26. Santaris Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Silence Therapeutics Basic Information, Manufacturing Base and Competitors
Table 28. Silence Therapeutics Major Business
Table 29. Silence Therapeutics Antisense and RNA Interference Therapeutics Product and Services
Table 30. Silence Therapeutics Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Sirnaomics Basic Information, Manufacturing Base and Competitors
Table 32. Sirnaomics Major Business
Table 33. Sirnaomics Antisense and RNA Interference Therapeutics Product and Services
Table 34. Sirnaomics Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Tekmira Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 36. Tekmira Pharmaceuticals Major Business
Table 37. Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product and Services
Table 38. Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Antisense and RNA Interference Therapeutics Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 40. Global Antisense and RNA Interference Therapeutics Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Antisense and RNA Interference Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Antisense and RNA Interference Therapeutics Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and Antisense and RNA Interference Therapeutics Production Site of Key Manufacturer
Table 44. Antisense and RNA Interference Therapeutics New Entrant and Capacity Expansion Plans
Table 45. Antisense and RNA Interference Therapeutics Mergers & Acquisitions in the Past Five Years
Table 46. Global Antisense and RNA Interference Therapeutics Sales by Region (2017-2022) & (K Units)
Table 47. Global Antisense and RNA Interference Therapeutics Sales by Region (2023-2028) & (K Units)
Table 48. Global Antisense and RNA Interference Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Antisense and RNA Interference Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Antisense and RNA Interference Therapeutics Sales by Type (2017-2022) & (K Units)
Table 51. Global Antisense and RNA Interference Therapeutics Sales by Type (2023-2028) & (K Units)
Table 52. Global Antisense and RNA Interference Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Antisense and RNA Interference Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Antisense and RNA Interference Therapeutics Price by Type (2017-2022) & (US$/Unit)
Table 55. Global Antisense and RNA Interference Therapeutics Price by Type (2023-2028) & (US$/Unit)
Table 56. Global Antisense and RNA Interference Therapeutics Sales by Application (2017-2022) & (K Units)
Table 57. Global Antisense and RNA Interference Therapeutics Sales by Application (2023-2028) & (K Units)
Table 58. Global Antisense and RNA Interference Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Antisense and RNA Interference Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Antisense and RNA Interference Therapeutics Price by Application (2017-2022) & (US$/Unit)
Table 61. Global Antisense and RNA Interference Therapeutics Price by Application (2023-2028) & (US$/Unit)
Table 62. North America Antisense and RNA Interference Therapeutics Sales by Country (2017-2022) & (K Units)
Table 63. North America Antisense and RNA Interference Therapeutics Sales by Country (2023-2028) & (K Units)
Table 64. North America Antisense and RNA Interference Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Antisense and RNA Interference Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Antisense and RNA Interference Therapeutics Sales by Type (2017-2022) & (K Units)
Table 67. North America Antisense and RNA Interference Therapeutics Sales by Type (2023-2028) & (K Units)
Table 68. North America Antisense and RNA Interference Therapeutics Sales by Application (2017-2022) & (K Units)
Table 69. North America Antisense and RNA Interference Therapeutics Sales by Application (2023-2028) & (K Units)
Table 70. Europe Antisense and RNA Interference Therapeutics Sales by Country (2017-2022) & (K Units)
Table 71. Europe Antisense and RNA Interference Therapeutics Sales by Country (2023-2028) & (K Units)
Table 72. Europe Antisense and RNA Interference Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Antisense and RNA Interference Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Antisense and RNA Interference Therapeutics Sales by Type (2017-2022) & (K Units)
Table 75. Europe Antisense and RNA Interference Therapeutics Sales by Type (2023-2028) & (K Units)
Table 76. Europe Antisense and RNA Interference Therapeutics Sales by Application (2017-2022) & (K Units)
Table 77. Europe Antisense and RNA Interference Therapeutics Sales by Application (2023-2028) & (K Units)
Table 78. Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Region (2017-2022) & (K Units)
Table 79. Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Region (2023-2028) & (K Units)
Table 80. Asia-Pacific Antisense and RNA Interference Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Antisense and RNA Interference Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Type (2017-2022) & (K Units)
Table 83. Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Type (2023-2028) & (K Units)
Table 84. Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Application (2017-2022) & (K Units)
Table 85. Asia-Pacific Antisense and RNA Interference Therapeutics Sales by Application (2023-2028) & (K Units)
Table 86. South America Antisense and RNA Interference Therapeutics Sales by Country (2017-2022) & (K Units)
Table 87. South America Antisense and RNA Interference Therapeutics Sales by Country (2023-2028) & (K Units)
Table 88. South America Antisense and RNA Interference Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Antisense and RNA Interference Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Antisense and RNA Interference Therapeutics Sales by Type (2017-2022) & (K Units)
Table 91. South America Antisense and RNA Interference Therapeutics Sales by Type (2023-2028) & (K Units)
Table 92. South America Antisense and RNA Interference Therapeutics Sales by Application (2017-2022) & (K Units)
Table 93. South America Antisense and RNA Interference Therapeutics Sales by Application (2023-2028) & (K Units)
Table 94. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Region (2017-2022) & (K Units)
Table 95. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Region (2023-2028) & (K Units)
Table 96. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type (2017-2022) & (K Units)
Table 99. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type (2023-2028) & (K Units)
Table 100. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application (2017-2022) & (K Units)
Table 101. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application (2023-2028) & (K Units)
Table 102. Antisense and RNA Interference Therapeutics Raw Material
Table 103. Key Manufacturers of Antisense and RNA Interference Therapeutics Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Antisense and RNA Interference Therapeutics Typical Distributors
Table 107. Antisense and RNA Interference Therapeutics Typical Customers
List of Figures
Figure 1. Antisense and RNA Interference Therapeutics Picture
Figure 2. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type in 2021
Figure 3. RNA
Figure 4. Antisense RNA
Figure 5. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application in 2021
Figure 6. General Hospitals
Figure 7. Specialty Clinics
Figure 8. Global Antisense and RNA Interference Therapeutics Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Antisense and RNA Interference Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Antisense and RNA Interference Therapeutics Sales (2017-2028) & (K Units)
Figure 11. Global Antisense and RNA Interference Therapeutics Price (2017-2028) & (US$/Unit)
Figure 12. Global Antisense and RNA Interference Therapeutics Production Capacity (2017-2028) & (K Units)
Figure 13. Global Antisense and RNA Interference Therapeutics Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Antisense and RNA Interference Therapeutics Market Drivers
Figure 15. Antisense and RNA Interference Therapeutics Market Restraints
Figure 16. Antisense and RNA Interference Therapeutics Market Trends
Figure 17. Global Antisense and RNA Interference Therapeutics Sales Market Share by Manufacturer in 2021
Figure 18. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Manufacturer in 2021
Figure 19. Antisense and RNA Interference Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Antisense and RNA Interference Therapeutics Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Antisense and RNA Interference Therapeutics Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Antisense and RNA Interference Therapeutics Sales Market Share by Region (2017-2028)
Figure 23. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Region (2017-2028)
Figure 24. North America Antisense and RNA Interference Therapeutics Revenue (2017-2028) & (USD Million)
Figure 25. Europe Antisense and RNA Interference Therapeutics Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Antisense and RNA Interference Therapeutics Revenue (2017-2028) & (USD Million)
Figure 27. South America Antisense and RNA Interference Therapeutics Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue (2017-2028) & (USD Million)
Figure 29. Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2028)
Figure 30. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2017-2028)
Figure 31. Global Antisense and RNA Interference Therapeutics Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2028)
Figure 33. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application (2017-2028)
Figure 34. Global Antisense and RNA Interference Therapeutics Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2028)
Figure 36. North America Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2028)
Figure 37. North America Antisense and RNA Interference Therapeutics Sales Market Share by Country (2017-2028)
Figure 38. North America Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2017-2028)
Figure 39. United States Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2028)
Figure 43. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2028)
Figure 44. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Country (2017-2028)
Figure 45. Europe Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2017-2028)
Figure 46. Germany Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Antisense and RNA Interference Therapeutics Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Antisense and RNA Interference Therapeutics Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Antisense and RNA Interference Therapeutics Revenue Market Share by Region (2017-2028)
Figure 55. China Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2028)
Figure 62. South America Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2028)
Figure 63. South America Antisense and RNA Interference Therapeutics Sales Market Share by Country (2017-2028)
Figure 64. South America Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Antisense and RNA Interference Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Antisense and RNA Interference Therapeutics in 2021
Figure 76. Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
Figure 77. Antisense and RNA Interference Therapeutics Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の小型干渉ネジ市場2022年：市場規模予測（～2028年）
  • 世界の生体吸収性干渉ネジ市場2022年：市場規模予測（～2028年）
  • 口腔乾燥症治療薬のグローバル市場展望 2023年-2029年：OTC、処方薬
  • 世界のガレクチン阻害治療薬市場2022年：市場規模予測（～2028年）
  • 世界の電磁＆無線周波数干渉コーティング市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19152 )"世界のアンチセンス＆RNA干渉治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Antisense and RNA Interference Therapeutics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。